LLY LLY
Eli Lilly Outlines Strategic Plan for Weight-Loss Drugs in India Ahead of Competitor Patent Expiry
Eli Lilly and Company's India head, Winselow Tucker, detailed the company's strategy to maintain its market lead for the weight-loss drug tirzepatide, marketed...
LLY Drops After Novo Nordisk Slashes Obesity Drug Prices
On November 17, 2025, Eli Lilly (LLY) shares declined after Novo Nordisk announced significant price reductions for its weight-loss drugs Wegovy and Ozempic,...
Eli Lilly Strikes $2.6 Billion Licensing Deal with ABL Bio for Antibody Technology
Eli Lilly and Company has entered into a significant licensing and joint research agreement with South Korean biotech firm ABL Bio for its bispecific antibody...
Eli Lilly Denies Partnership with Telehealth Firm Mangoceuticals for Weight-Loss Drugs
Eli Lilly and Company has publicly denied any partnership with telehealth provider Mangoceuticals for the distribution of its popular weight-loss medications....
Eli Lilly Stock Reaches New All-Time High
Eli Lilly's stock surged to a new all-time high of $1022.62 on November 14, 2025, continuing its strong performance. This milestone reflects significant...
Eli Lilly's Blockbuster Drugs Single-Handedly Drive Ireland's 2025 GDP Growth by 11%
A report from The Irish Times on November 12, 2025, revealed that Eli Lilly's blockbuster weight-loss drugs, Mounjaro and Zepbound, are the primary drivers...
Eli Lilly Drops CVS Drug Benefit Plan for Employees in Formulary Dispute
Eli Lilly is set to drop CVS Health's drug benefit plan for its own employees, with the change taking effect on January 1. The company will transition its...
Eli Lilly Surges on Strategic R&D Shift, Hits New Highs
On November 11, 2025, Eli Lilly shares surged 4.54% in pre-market trading following announcements of a strategic expansion in diabetes and oncology R&D, and a...
Eli Lilly and Novo Nordisk Strike Deal with Trump Administration to Lower GLP-1 Drug Prices
Eli Lilly and Company, along with competitor Novo Nordisk, has reached an agreement with the Trump administration to substantially reduce the prices of their...
Eli Lilly Stock Hits Record Highs Amid Analyst Actions and Strong Q3
On November 10, 2025, Eli Lilly (LLY) stock closed at $966.64, up 4.57%, marking a new all-time high and reflecting strong investor enthusiasm[3]. The surge...
Eli Lilly Expands into Gene Therapy and RNAi with Strategic Collaborations
Eli Lilly and Company announced significant strategic collaborations to expand its pipeline into genetic medicines. The company partnered with MeiraGTx to...
Eli Lilly Expands into Ophthalmic Gene Therapy with $475M MeiraGTx Collaboration
Eli Lilly and Company announced a strategic licensing deal with MeiraGTx to develop gene therapies for eye diseases, marking a significant expansion into...
Eli Lilly Enters $1.2B Licensing Deal for RNAi Metabolic Disease Therapeutics
Eli Lilly and Company has entered into a significant research and licensing agreement with SanegeneBio to discover, develop, and commercialize RNA interference...
Eli Lilly Expands Executive Team to Drive Neuroscience and Immunology Growth
Eli Lilly and Company announced the appointment of two new members to its executive committee and the expansion of roles for other senior leaders to support...
Eli Lilly Faces Michigan Supreme Court Over Insulin Pricing Probe
The Michigan Supreme Court heard oral arguments in a case brought by the state's attorney general against Eli Lilly concerning its insulin pricing. The...
Eli Lilly's Stock Price Target Increased to $1,100 by BMO Capital
BMO Capital Markets has raised its price target for Eli Lilly to $1,100 from $930, maintaining an Outperform rating. This significant increase is attributed to...
Eli Lilly Enters AI-Powered Antibody Discovery Collaboration with Ailux
Eli Lilly and Company has entered into a strategic collaboration with Ailux, a subsidiary of XtalPi, to discover and develop bispecific antibodies. The...
Eli Lilly Deepens China Commitment at CIIE with New Innovation Hub and Showcase of Key Drugs
On November 5, 2025, Eli Lilly and Company highlighted its expanding commitment to the Chinese market at the 8th China International Import Expo (CIIE) in...
Eli Lilly Stock Rises on Substantial Progress Announcement
On November 4, 2025, Eli Lilly and Company shares rose 1.13% to $906.69, continuing a strong multi-day rally. The price movement was driven by news that the...
Eli Lilly and Novo Nordisk Reportedly Nearing US Deal to Lower Obesity Drug Prices for Medicare Coverage
Eli Lilly and Novo Nordisk are reportedly nearing a deal with the White House to lower the prices of their popular obesity drugs in exchange for securing...